Serial investors: Comforting figures for VC backers
The San Diego Business Journal profiles serial entrepreneur Randy Woods, who has raised $20 million so far to back Sequel Pharmaceuticals, a spin-off from NovaCardia. Woods had been the CEO of NovaCardia when it was sold to Merck for $364 million last fall. Earlier, Woods had run Corvas International, which was sold to Dendreon in '03 after a failed clinical trial. Woods' new venture is focused on developing an experimental therapy for arrhythmia.
What Woods finds exciting: "It's being on the edge of the technology that's the next newest and biggest thing." Sounds exciting, but Woods also notes that venture capitalists like to see familiar faces at the helm of those cutting-edge startups.
- read the article from the San Diego Business Journal
Related Articles:
VC adds billions in its pursuit of biotech ventures. Report
Biotech entrepreneur turns talents to venture fund. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
